ClinicalTrials.gg
RecruitingNCT06894797Updated Mar 25, 2025

Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer.

An interventional study of Concurrent Chemoradiotherapy(Radiation + Capecitabine) and irinotecan hydrochloride liposome injection in Locally Advanced Rectal Cancer, sponsored by Peking University Cancer Hospital & Institute. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-25.

Sponsored by Peking University Cancer Hospital & Institute · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 92 studies testing irinotecan in Rectal Neoplasms — 4 open to participants now, 8 under way, 2 of them phase 3. Irinotecan · Rectal Neoplasms.

Planned enrollment
28th of 77
68 · median 50
Started
2025
the only one that year
No phase
2 of 92
1 open now
Registered
91st of 92
by date

Among the 92 studies testing irinotecan in Rectal Neoplasms, this one is the 28th largest by planned enrollment of the 77 interventional ones that give a count, is the only one that started in 2025, is one of 2 with no phase, and was the 91st registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

4 of the 92 studies testing irinotecan in Rectal Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About irinotecan

Irinotecan: first FDA approval 1996 (CAMPTOSAR), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies testing irinotecan in Rectal Neoplasms, or all of them as a file.
02

Study summary

The Efficacy and Safety of Long-Course Preoperative Chemoradiotherapy Combined with Consolidation or Induction NALIRIFOX Chemotherapy in the Treatment of Locally Advanced Rectal Cancer: A Prospective, Multicenter, Phase II Study.

03

Conditions studied

  • Locally Advanced Rectal Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects participate in the study need to sign the , and demonstrate good compliance.
  2. Age: 18\~75 years old.
  3. Histopathologically confirmed rectal adenocarcinoma.
  4. Locally advanced rectal cancer, determined at baseline.
  5. No prior systemic therapy.
  6. (ECOG) performance status of 0\~1.
  7. Expected survival ≥ 12 months.
  8. Adequate bone marrow function (In the absence of blood transfusion within 14 days, correction with granulocyte colony-stimulating factor or other hematopoietic stimulating factor was not used within 7 days prior to laboratory examination) :

    ① (ANC) ≥1.5×10\^9/L, count ≥100×10\^9/L, (Hb) ≥9g/dL.

    ② Liver function: Total ≤1.5 × (ULN), (AST) and alanine aminotransferase (ALT) ≤2.5×ULN, liver , AST and ALT≤5×ULN.

    ③ Renal function: Serum creatinine (Cr) ≤1.5 × ULN or ≥60 mL/min.

    ④ (INR) ≤ 1.5 ULN, Prothrombin time and activated partial thromboplastin time (APTT) ≤ 1.5 ULN

  9. Microsatellite Stability (MSS) or proficient MisMatch Repair (pMMR).

Exclusion criteria

Exclusion Criteria:

  1. Within 4 weeks prior to treatment, subjects must not have received radiotherapy, surgery, chemotherapy, immunotherapy for tumors, molecular targeted therapies, or other drugs.
  2. microsatellite instability (MSI) or mismatch repair gene deletion (dMMR)
  3. Distant
  4. Significant clinical bleeding symptoms or significant bleeding tendency within 3 months prior to treatment (bleeding > 30ml within 3 months), hematemesis, black stool, blood in the stool), hemoptysis (> 5 mL of fresh blood within 4 weeks), etc. Treatment of venous/venous thrombotic events within the first 6 months, such as cerebrovascular accidents (including transient brain lesions) Ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism; Or need to use warfarin or Long-term anticoagulant therapy with heparin, or long-term antiplatelet therapy (aspirin ≥300 mg/day or chlorine) is required Picogrel ≥75 mg/day).
  5. During screening, tumors were found to invade large vascular structures, such as pulmonary artery, superior vena cava or inferior vena cava that there was a risk of major bleeding by the investigator judged.
  6. Active heart disease, including myocardial infarction, severe/unstable angina, occurred 6 months before treatment. ultrasonic \<50% was detected by cardiogram, indicating poor arrhythmia control.
  7. High blood pressure that is not well controlled by antihypertensive medication (systolic blood pressure ≥140 mmHg and/or diastolic pressure ≥90 mmHg).
  8. Any other within 5 years, with the exception of cured in-situ carcinoma or basal cell carcinoma etc.
  9. Known or suspected allergy to the investigational drug or a similar drug.
  10. Active or uncontrolled severe infection.
  11. Known (HIV) infection.
  12. Any other disease with metabolic abnormalities, physical abnormalities, or laboratory abnormalities Often, in the investigator's judgment, there is reason to suspect that the patient has a disease or condition that is not suitable for use of the investigational drug state (such as having a seizure and requiring treatment) that will either affect the interpretation of the study results or make the patient In a high-risk situation.
  13. Patients who have been co-administered a potent inducer within 3 weeks prior to first dosing, or a potent CYP3A4 inhibitor or a potent UGT1A1 inhibitor within 3 weeks prior to first dosing
  14. Inability to comply with study protocols or study procedures.
  15. Patients who are not suitable to participate in this trial judged by the investigator.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Long-Course Preoperative Chemoradiotherapy Combined with Consolidation NALIRIFOX Chemotherapy

    Patients will receive Concurrent Chemoradiotherapy(Radiation + Capecitabine) followed by NALIRIFOX Concurrent Chemoradiotherapy:5 Weeks in total NALIRIFOX:8 Weeks in total

    Radiation: Concurrent Chemoradiotherapy(Radiation + Capecitabine) · Drug: irinotecan hydrochloride liposome injection · Drug: Oxaliplatin · Drug: 5-FU

  • Experimental
    Long-Course Preoperative Chemoradiotherapy Combined with Induction NALIRIFOX Chemotherapy

    Patients will receive NALIRIFOX followed by Concurrent Chemoradiotherapy(Radiation + Capecitabine) Concurrent Chemoradiotherapy:5 Weeks in total NALIRIFOX:8 Weeks in total

    Radiation: Concurrent Chemoradiotherapy(Radiation + Capecitabine) · Drug: irinotecan hydrochloride liposome injection · Drug: Oxaliplatin · Drug: 5-FU

Interventions

  • RadiationConcurrent Chemoradiotherapy(Radiation + Capecitabine)

    Capecitabine 825 mg/m\^2 Po BlD, Monday-Friday, on days of radiation treatment only, throughout the duration of RT Radiation:45-50Gy/25fractions/5 weeks,5fractions/week

  • DrugIrinotecanStudies of IrinotecanIrinotecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Irinotecan hydrochloride liposome injection (50mg/m\^2) will be administered by intravenous infusion on day 1 in a 2-week treatment cycle.

    Also known as: Nal-IRI

  • Oxaliplatin (60mg/m\^2) will be administered by intravenous infusion on day 1 in a 2-week treatment cycle.

    Also known as: OXA

  • DrugFluorouracilStudies of FluorouracilFluorouracil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    5-FU (2400mg/m\^2) will be administered by intravenous infusion on 46h in a 2-week treatment cycle.

    Also known as: fluorouracil

06

What researchers measure

Primary outcomes

  1. Pathological complete response rate

    To evaluate the efficacy of anti-tumor

    Time frame: From baseline up to approximately 3 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2025; primary completion for Oct 2026, 18 months later.

Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 18 months is below that.

Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2025
First posted
Mar 25, 2025
StartEst.
Apr 1, 2025
Primary completionEst.
Oct 31, 2026
CompletionEst.
Oct 31, 2027
Last update
Mar 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06894797
Responsible party
Yongheng Li (Director, Peking University Cancer Hospital & Institute) — Principal investigator
First posted
Mar 25, 2025
Start date
Apr 1, 2025 (estimated)
Primary completion
Oct 31, 2026 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Mar 25, 2025

Study contacts

Yongheng Li, MD
Contact
yonghenglee@163.com
13810277398
Xicheng Wang, MD
Contact
13439563949
Yongheng Li, MD
principal investigator · Peking University Cancer Hospital & Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Irinotecan · Oxaliplatin · Fluorouracil

Start the discussion